OncoMatch/Leukemia — Acute Myeloid (AML)/RUNX1
Leukemia — Acute Myeloid (AML)RUNX1 Clinical Trials
RUNX1 mutations occur in 10–15% of AML, classified as adverse-risk by ELN 2022 guidelines, and are often associated with antecedent MDS or myelodysplastic features. RUNX1-mutant AML is a component of familial platelet disorder with predisposition to AML (FPD-AML) and has a distinct transcriptional profile. Trials explore menin inhibitors, venetoclax-based regimens, and novel agents targeting co-occurring mutations in this subgroup.
Top recruiting RUNX1 Leukemia — Acute Myeloid (AML) trials
Ranked by phase and US site count. See all 15 trials matched to your profile →
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
M.D. Anderson Cancer Center
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Washington University School of Medicine